JPRN-UMIN000041707
Not yet recruiting
未知
The clinical study investigating the effect of pemafibrate administration on cardiac diastolic function in patients with type 2 diabetes - The effect of pemafibrate on cardiac diastolic function in patients with type 2 diabetes
Yamaguchi University, Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Department of Bio-Signal Analysis0 sites20 target enrollmentSeptember 23, 2020
ConditionsType 2 diabetes, Dyslipidemia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 diabetes, Dyslipidemia
- Sponsor
- Yamaguchi University, Graduate School of Medicine, Division of Endocrinology, Metabolism, Hematological Science and Therapeutics, Department of Bio-Signal Analysis
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Who has a history of fibrate exposure within 6 months. 2\) Who suffers from atrial fibrillation. 3\) Who is judged by the investigators to be inappropriate for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A clinical study to discover the involvement of periodontal disease with circulative diseases in Japan and Asian countriesCardiovascular diseases, Periodontal diseaseJPRN-UMIN000017027Advanced Clinical Sciense and Therapeutics, the University of Tokyo2,000
Not yet recruiting
Phase 2
Ayurveda management of Chronic tonsillitis in childreHealth Condition 1: J350- Chronic tonsillitis and adenoiditisCTRI/2020/08/027344SDM College of Ayurveda and Hospital
Completed
Not Applicable
A Clinical study to evaluate the effects of factors during surgery to predict outcome and patient satisfaction in patients undergoing general surgery under anesthesiaCTRI/2020/01/022901Adichunchanagiri medical college250
Active, not recruiting
Phase 1
A Clinical Trial for Newly Diagnosed High Risk ER+/HER2– (Estrogen Receptor Positive/ Human Epidermal growth factor receptor Negative) Breast CancerHigh-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast CancerMedDRA version: 20.1Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-004869-27-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,140
Active, not recruiting
Phase 1
A Phase III Study to Evaluate Chemotherapy With or Without Pembrolizumab as First Line Treatment for Triple Negative Breast CancerEUCTR2016-001432-35-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.858